相关临床试验
99
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1969
进行中（未招募）
3
3.0%
已完成
48
48.5%
尚未招募
3
3.0%
招募中
10
10.1%
终止
17
17.2%
Unknown
1
1.0%
撤回
17
17.2%
暂无批准数据
- A real-world analysis of over 1,500 patients found significantly higher relapse risk and inferior survival in males versus females treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma. - The progression-free survival and overall survival differences were significant and more pronounced among patients younger than 50 years. - Researchers attribute the disparity to sex hormone effects on immune responses, including estradiol-driven upregulation of CD4+ T-cells and immunosuppressive properties of androgens. - The authors call for broad-based sex differences to be incorporated into CAR-T studies and plan prospective validation of sex-specific differences in cell therapy outcomes.
- New research from Texas Tech University Health Sciences Center shows racial and ethnic minority women with cancer face up to 40% higher risk of adverse pregnancy outcomes compared to their white counterparts. - The study, presented at the American Association for Cancer Research Annual Meeting 2025, found particularly elevated risks for women with breast and thyroid cancers, with a 30% increase in complications. - Researchers highlight the need for more comprehensive clinical guidelines and personalized care approaches that consider pre-existing conditions, socioeconomic factors, and treatment modalities during pregnancy.
- Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials. - The oral medication muvalaplin works by preventing apolipoprotein B and apolipoprotein A molecules from binding, while zerlasiran uses small interfering RNA to target the underlying gene. - These developments represent a significant advancement in cardiovascular medicine, as elevated lipoprotein(a) is a genetically determined risk factor that previously had no effective treatment options.
• Considerations for discontinuing Keytruda (pembrolizumab) and Inlyta (axitinib) after two years involve balancing recurrence risk and side effects, necessitating individualized patient-physician discussions. • For non-clear cell chromophobe renal cell carcinoma, IO-TKI combinations like Lenvima (lenvatinib) plus Keytruda or Cabometyx (cabozantinib) plus Opdivo (nivolumab) show promise, with treatment choice depending on approval status. • Managing fatigue and chronic kidney disease in RCC patients requires investigating reversible causes and employing supportive measures, with nephrologist involvement for significant renal impairment.
